Lenvatinib Plus Programmed Cell Death Protein-1 (PD-1) Inhibitor Versus Lenvtinib Alone for Advanced Hepatocellular Carcinoma: a Multicentre Randomised Controlled Trial
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 06 May 2019
Price : $35 *
At a glance
- Drugs Lenvatinib (Primary) ; Antineoplastics
- Indications Liver cancer
- Focus Therapeutic Use
- 30 Apr 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 05 Mar 2019 Planned initiation date changed from 21 Jan 2019 to 21 Apr 2019.
- 26 Nov 2018 Status changed from recruiting to not yet recruiting.